Glaxo Uses Contests To Target Young Hopefuls And Academic Minds
This article was originally published in The Pink Sheet Daily
With a view to front-loading GlaxoSmithKline’s pipeline, the drug maker’s venture capital arm SR One is increasingly targeting early prospects – to the point of running intense entrepreneurial competitions to fan the flames of innovation in Europe and tap into early startups there.
You may also be interested in...
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.